Market revenue in 2023 | USD 3,028.0 million |
Market revenue in 2030 | USD 4,875.4 million |
Growth rate | 7% (CAGR from 2023 to 2030) |
Largest segment | Traditional active pharmaceutical ingredient (traditional api) |
Fastest growing segment | Antibody Drug Conjugate (ADC |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Traditional Active Pharmaceutical Ingredient (Traditional API), Highly Potent Active Pharmaceutical Ingredient (HP-API), Antibody Drug Conjugate (ADC |
Key market players worldwide | Recipharm, Thermo Fisher Scientific Inc, Samsung BioLogics, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Piramal Pharma Solutions, Boehringer Ingelheim, Cambrex, CordenPharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to active pharmaceutical ingredient cdmo market will help companies and investors design strategic landscapes.
Traditional active pharmaceutical ingredient (traditional api) was the largest segment with a revenue share of 39.84% in 2023. Horizon Databook has segmented the Italy active pharmaceutical ingredient cdmo market based on traditional active pharmaceutical ingredient (traditional api), highly potent active pharmaceutical ingredient (hp-api), antibody drug conjugate (adc covering the revenue growth of each sub-segment from 2018 to 2030.
Italy held a 7.4% share in Europe’s market in 2020. It is expected to exhibit lucrative growth over the forecast period owing to stringent regulatory policies. Pharmaceutical Service of Ministry of Health is responsible for regulating the marketing of APIs in the country.
Furthermore, according to Pharma World, productivity per unit of the pharma sector in the country was nearly 10% higher than the European mean in 2018, highlighting the availability of skilled labor in the country, which is expected to create growth opportunities for active pharmaceutical ingredient CDMOs.
Growing number of clinical trials in the country is projected to create opportunities for the CDMOs. According to WHO ICTRP, 26,449 clinical trials were conducted in Italy between 1999 and 2020.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy active pharmaceutical ingredient cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Italy active pharmaceutical ingredient cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account